Addyi Cost in Utah 2026: Flibanserin Pricing, Coverage, and Savings Options

What Is Addyi and Why Does It Cost So Much in Utah?

Addyi (flibanserin 100 mg oral tablet) is the only FDA-approved non-hormonal treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. Sprout Pharmaceuticals holds the brand monopoly, and no FDA-approved generic exists as of 2026, which keeps the list price fixed at $880 per month across retail pharmacy channels in Utah.

Flibanserin is a 5-HT1A agonist and 5-HT2A antagonist that acts centrally on serotonin and dopamine pathways rather than on sex hormones [1]. The FDA approved it in August 2015 under a Risk Evaluation and Mitigation Strategy (REMS) because of a clinically significant interaction with alcohol [2]. That REMS requirement adds a layer of specialty-pharmacy routing that pharmacy benefit managers (PBMs) can use to restrict access, and it contributes to the drug's pricing architecture.

The BEGONIA trial (N=1,378, published J Sex Med 2014) showed flibanserin 100 mg at bedtime produced a statistically significant increase in satisfying sexual events compared with placebo (P<0.001) and a meaningful reduction in distress scores on the Female Sexual Distress Scale [3]. A later pooled analysis of three Phase 3 trials (N=2,400) reported that roughly 10% more women in the flibanserin arm achieved a minimally clinically important difference on the FSDS-R compared with placebo [4]. The efficacy data are modest but consistent enough that the Endocrine Society and the International Society for the Study of Women's Sexual Health (ISSWSH) both recognize flibanserin as an evidence-based option for HSDD [5].

Because no generic is available and the brand name commands $880/month, Utah patients face one of three routes: commercial insurance with a savings card, a 503A compounding pharmacy, or a manufacturer assistance program. Each route has distinct eligibility rules and caveats, detailed in the sections below.

Addyi Cash Price at Utah Pharmacies in 2026

The cash price for a 30-tablet supply of Addyi 100 mg at major Utah retail chains (Smith's, Harmons, Walgreens, CVS) is approximately $880 per month as of early 2026. This matches the Sprout Pharmaceuticals manufacturer suggested retail price.

No FDA-approved generic flibanserin has passed through the Orange Book approval process, so GoodRx and similar coupon platforms have limited ability to discount brand-name Addyi below $800 to $850 at most Utah zip codes. The FDA's drug shortage and generic drug databases confirm no approved generic applicant has received tentative approval as of 2025 [2].

Patients who fill Addyi at a specialty pharmacy certified under the REMS program may see slightly different pricing structures depending on the specific pharmacy network their prescriber uses. The REMS program mandates that both prescribers and dispensing pharmacies be certified [2]. In Utah, several retail and mail-order pharmacies hold that certification. Calling ahead to confirm REMS certification before transfer is worth the two-minute call.

GoodRx coupons at the time of this writing show Addyi pricing ranging from $815 to $870 at Utah retailers. Because GoodRx prices change weekly and cannot always be used simultaneously with insurance, patients should verify at the pharmacy counter before filling.

Utah Medicaid Does Not Cover Addyi

Utah Medicaid's preferred drug list does not include flibanserin as a covered medication. Addyi is not covered under standard Utah Medicaid fee-for-service plans or managed care organization (MCO) contracts as of 2026.

Patients enrolled in Utah Medicaid, including the Healthy Utah expansion population, cannot currently obtain flibanserin through the state formulary. The exclusion is consistent with coverage patterns in most state Medicaid programs. A 2021 analysis in JAMA Internal Medicine found that HSDD treatments including flibanserin faced disproportionate formulary exclusions compared with erectile dysfunction drugs at similar efficacy levels, reflecting longstanding sex-based disparities in benefit design [6]. Advocates for coverage parity have cited this disparity before state pharmacy and therapeutics (P&T) committees, though Utah's formulary had not changed as of this article's review date.

Patients on Medicaid who believe they have a medical necessity argument may submit a prior authorization (PA) exception request through their MCO, but approval is rare given the blanket categorical exclusion. An ISSWSH position statement notes that "HSDD is a recognized medical condition with validated diagnostic criteria and FDA-approved pharmacotherapy," arguing that coverage exclusions fail the standard of medical necessity review [5].

If a PA is denied, the Sprout Patient Assistance Program (see below) is the primary fallback for low-income patients.

Commercial Insurance Coverage for Addyi in Utah

Coverage varies sharply by plan. Most commercial insurance plans in Utah classify Addyi as a Tier 3 or Tier 4 specialty drug, which translates to copays between $150 and $400 per month even when the drug is technically "covered." Some plans require a prior authorization, step therapy through a trial of psychotherapy or a serotonin-norepinephrine reuptake inhibitor (SNRI), or both.

Utah-based employers who self-fund their health plans often follow the exclusion patterns set by their PBM. Express Scripts and CVS Caremark, the two dominant PBMs operating in Utah, place Addyi in a specialty tier that requires PA in the majority of their commercial formularies. OptumRx formularies show broader variation, with some national employer plans covering Addyi at a $50 to $80 specialty copay when paired with the Sprout savings card.

The Affordable Care Act's preventive care mandate does not apply to Addyi because HSDD pharmacotherapy has not received a USPSTF Grade A or B rating [7]. That means insurers are not required to cover it without cost sharing.

Calling the member services number on the back of your insurance card and asking specifically for the "formulary status and prior authorization requirements for NDC 59148-0006-30" is the fastest way to get an accurate answer before your prescriber submits the prescription.

How the Sprout Pharmaceuticals Savings Card Works in Utah

Sprout Pharmaceuticals offers a copay savings card that can bring out-of-pocket cost to as low as $0 per month for eligible commercially insured patients. The card functions as a secondary payer, covering the gap between what insurance pays and what the patient owes, up to a monthly maximum.

Eligibility requirements for the Sprout savings card include:

• Commercial (private) insurance that covers Addyi at any level
• Residency in the United States (Utah qualifies)
• No government insurance as primary payer (Medicaid, Medicare, TRICARE disqualify)
• Enrollment through the Addyi.com savings portal or directly at the REMS-certified pharmacy

For patients whose commercial plan has placed Addyi on a high-cost specialty tier, the savings card may cover up to $840 per fill, effectively reducing cost to $0. The program refreshes annually. Patients must re-enroll each calendar year.

The HealthRX clinical team uses the following decision sequence when counseling Utah patients about Addyi affordability:

1. Confirm commercial insurance status. If commercial coverage exists, check formulary tier and PA requirements first.
2. Pair the Sprout savings card with commercial coverage to minimize copay.
3. If uninsured or on Medicaid, evaluate the Sprout Patient Assistance Program (income-based free drug program).
4. If ineligible for manufacturer assistance, assess whether compounded flibanserin from a Utah-licensed 503A pharmacy is an appropriate alternative given the patient's clinical profile.
5. Telehealth prescribing is available in Utah and does not change eligibility for any of the above cost programs.

Patients with Medicare Part D face a separate challenge. The savings card cannot legally be used by Medicare beneficiaries. Because Addyi is indicated only for premenopausal women and the FDA label excludes postmenopausal use, Medicare coverage is rarely relevant clinically. If a premenopausal woman under 65 has Medicare due to disability, the Extra Help (Low Income Subsidy) program through CMS is the most likely assistance route [8].

Compounded Flibanserin in Utah: What Is Legal and What Is Not

Compounded flibanserin dispensed by a 503A pharmacy is legal in Utah under state pharmacy law and federal Section 503A of the Federal Food, Drug, and Cosmetic Act, provided specific conditions are met [9].

A 503A pharmacy compounds flibanserin for an individual patient based on a valid prescription from a licensed prescriber. These pharmacies operate under state board of pharmacy oversight and must use a bulk drug substance that meets USP standards. The compound is not FDA-approved and is not subject to the Addyi REMS. This means the pharmacist cannot guarantee the same bioavailability or alcohol-interaction profile as the brand product. Patients who choose compounded flibanserin should receive explicit counseling on that distinction.

The FDA has not placed flibanserin on its 503A Bulks List (the list of substances that may NOT be compounded), which is why 503A compounding is currently permissible [9]. If the FDA were to add flibanserin to the Bulks List in a future rulemaking cycle, 503A compounding would become prohibited. Patients should confirm current status with their prescriber or Utah State Board of Pharmacy at the time of prescribing.

503B outsourcing facilities (large-scale compounders supplying hospitals and clinics without patient-specific prescriptions) are not permitted to compound flibanserin because Addyi is a commercially available FDA-approved drug and 503B facilities may not compound copies of commercially available drugs without a shortage designation [9]. Any Utah provider offering "bulk-compounded" flibanserin without a patient-specific prescription may be operating outside legal bounds.

The cost of compounded flibanserin at Utah 503A pharmacies varies by pharmacy but is generally $40 to $120 per month, making it a meaningful alternative for uninsured patients who cannot access the Sprout savings card. Quality and dosing accuracy can vary between compounders, so HealthRX recommends using a pharmacy that participates in an accreditation program such as PCAB (Pharmacy Compounding Accreditation Board).

Getting Addyi via Telehealth in Utah

Telehealth prescribing of flibanserin is permitted in Utah. Utah Code Section 26B-4-406 allows prescribers to establish a valid patient-provider relationship via synchronous audio-visual telehealth before issuing a Schedule V controlled substance prescription, which satisfies federal DEA requirements for prescribing controlled substances via telemedicine [10].

The practical workflow for a Utah patient seeking Addyi through a telehealth platform:

• Complete a video or synchronous audio-visual consultation with a licensed Utah prescriber (MD, DO, APRN with prescriptive authority, or PA with appropriate collaboration agreement).
• The prescriber confirms the HSDD diagnosis using validated tools such as the Decreased Sexual Desire Screener (DSDS) or Female Sexual Function Index (FSFI).
• If flibanserin is appropriate, the prescriber sends a prescription to a REMS-certified pharmacy in Utah or a REMS-certified mail-order pharmacy licensed to dispense in Utah.
• The patient (or pharmacy) enrolls in the Sprout savings program if commercially insured.

The DEA's 2024 telehealth prescribing rules, finalized after the COVID-19 public health emergency expired, require a synchronous two-way audio-visual interaction for Schedule V substances unless the prescriber has seen the patient at least once in person [10]. Audio-only telehealth is not sufficient for an initial flibanserin prescription under current federal rules.

HealthRX connects Utah patients with board-certified gynecologists and women's health nurse practitioners licensed in Utah who can complete the initial HSDD evaluation and, when appropriate, submit the Addyi prescription directly to a REMS-certified pharmacy.

Clinical Eligibility: Who Can Receive Addyi in Utah

Flibanserin is FDA-approved specifically for premenopausal women with acquired, generalized HSDD. The FDA label specifies the following contraindications and precautions that prescribers must confirm before issuing a prescription [2]:

• Alcohol use: patients must agree to abstain from alcohol, because the combination can cause severe hypotension and syncope.
• Hepatic impairment: Addyi is contraindicated in patients with any degree of hepatic impairment.
• Strong or moderate CYP3A4 inhibitors: drugs such as fluconazole, ketoconazole, and certain HIV antiretrovirals are contraindicated with flibanserin due to a 7-fold increase in flibanserin exposure [2].
• Hypotension: flibanserin carries a Black Box Warning related to hypotension and syncope, particularly in combination with alcohol or CYP3A4 inhibitors.

The BEGONIA trial (N=1,378) evaluated flibanserin 100 mg at bedtime against placebo over 24 weeks and found a mean increase of 0.7 satisfying sexual events per month versus 0.4 for placebo, along with significant improvements in desire and distress scores [3]. The effect size is modest, and the FDA's own advisory panel noted that patient-centered outcome measures showed a clinically meaningful response in roughly 10% more treated patients than placebo [4]. Patients should receive this information before starting therapy so they can weigh benefit against the real-world constraints of alcohol abstinence and drug interactions.

A 2022 ISSWSH clinical practice guideline recommends that HSDD diagnosis be confirmed with validated patient-reported outcome instruments and that contributing factors such as relationship distress, depression, or SSRI-induced sexual dysfunction be addressed concurrently [5]. Flibanserin does not treat SSRI-induced sexual dysfunction; bupropion augmentation or dose reduction is the preferred approach in that context.

Utah-Specific Prescriber and Pharmacy Considerations

Utah has a higher-than-average proportion of patients using Latter-day Saint Deseret Mutual Benefit Administrators (DMBA) insurance. DMBA plans are self-funded and not subject to ACA essential health benefit mandates, which means their formularies can exclude Addyi entirely. DMBA beneficiaries should call plan member services directly before assuming any coverage.

University of Utah Health Plans and SelectHealth (Intermountain Health's insurer) have both listed Addyi as a covered specialty drug with prior authorization on at least some commercial product lines as of 2025. Coverage status changes annually at the January 1 formulary reset.

Patients in rural Utah (outside the Wasatch Front) may find that no local pharmacy holds REMS certification. In that scenario, mail-order through a REMS-certified national pharmacy (REMS-certified online pharmacies include some large mail-order operations licensed in Utah) is the practical solution. The prescribing telehealth provider can typically coordinate the mail-order fill as part of the enrollment workflow.

Side Effects That May Affect Treatment Continuation

Side effects influence whether a patient stays on therapy long enough to see benefit. The most common adverse effects reported in Phase 3 trials were dizziness (11.4% flibanserin vs. 2.2% placebo), somnolence (11.2% vs. 2.9%), nausea (10.4% vs. 4.1%), and fatigue (9.2% vs. 5.5%) [2]. Most side effects were mild to moderate and resolved within the first four weeks of therapy.

Because flibanserin is taken at bedtime, somnolence typically does not impair daytime function. Prescribers should instruct patients not to take the first dose on a night when they have consumed any alcohol, even at dinner, given the hypotension risk. Driving or operating machinery the morning after the first few doses may be affected in some patients.

The FDA label recommends discontinuing flibanserin if no improvement in HSDD symptoms is seen after eight weeks at 100 mg nightly [2]. This time-limited trial period is a useful framing for patients who are paying out of pocket and need to know whether the drug is working before continuing a costly prescription.

Monitoring and Follow-Up After Starting Addyi

After a prescription is issued, the monitoring requirements for flibanserin are relatively limited compared with hormonal HSDD therapies. No routine laboratory monitoring is required by the FDA label [2]. Blood pressure should be assessed at baseline given the hypotension risk, particularly in patients who also take antihypertensive medications or have known orthostatic hypotension.

The REMS requires that patients sign a Patient-Provider Agreement Form acknowledging the alcohol interaction risk before the pharmacy can dispense the medication [2]. This form is part of the REMS enrollment and is typically completed electronically for telehealth prescriptions.

Follow-up at four to eight weeks allows the prescriber to assess whether the patient has experienced the satisfying sexual event increase or distress reduction that defines a treatment response. If symptoms have not improved at the eight-week mark, the FDA label supports discontinuation and consideration of alternative management, which may include ospemifene (for concurrent genital arousal concerns in perimenopausal patients), sex therapy referral, or watchful waiting.